Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

NCT03586297 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT03586297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03586297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
Lead sponsor
Hackensack Meridian Health
Phase
Observational
Overall status
Completed
Start date
August 27, 2017
Completion date
September 15, 2025
Enrollment
49 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer